Press Releases Items Per Page 102550 Year None20192018201720162015201420132012201120102007 01.20.16 Allan L. Shaw Joins Syndax Pharmaceuticals as Chief Financial Officer Syndax_Allan_Shaw_CFO_20Jan2016.pdf 01.04.16 Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer 12.03.15 Syndax Announces Multiple Data Presentations On Entinostat At Upcoming San Antonio Breast Cancer Symposium 12.01.15 Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin 09.28.15 Syndax And Merck Announce First Patients Dosed In Phase 1b/2 Clinical Trial Of Entinostat And Keytruda® Syndax-Merck-601-Ph1b2-Initiation-09-28-15.pdf 09.16.15 Syndax to Present at Two Upcoming Scientific Conferences 09.01.15 Michael Meyers, M.D., Ph.D., Joins Syndax Pharmaceuticals as SVP and Chief Development Officer 08.26.15 Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab 08.24.15 Syndax Raises $80 Million in Series C Financing 06.15.15 Syndax Appoints Dr. Briggs W. Morrison as Chief Executive Officer and Michael A. Metzger as President and Chief Operating Officer 03.31.15 Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma 03.12.15 Syndax to Participate in Two Upcoming Conferences Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last »
01.20.16 Allan L. Shaw Joins Syndax Pharmaceuticals as Chief Financial Officer Syndax_Allan_Shaw_CFO_20Jan2016.pdf
01.04.16 Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer
12.03.15 Syndax Announces Multiple Data Presentations On Entinostat At Upcoming San Antonio Breast Cancer Symposium
12.01.15 Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin
09.28.15 Syndax And Merck Announce First Patients Dosed In Phase 1b/2 Clinical Trial Of Entinostat And Keytruda® Syndax-Merck-601-Ph1b2-Initiation-09-28-15.pdf
09.01.15 Michael Meyers, M.D., Ph.D., Joins Syndax Pharmaceuticals as SVP and Chief Development Officer
08.26.15 Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab
06.15.15 Syndax Appoints Dr. Briggs W. Morrison as Chief Executive Officer and Michael A. Metzger as President and Chief Operating Officer
03.31.15 Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
